Department of Stomatology, Xiangya Hospital, Central South University, Changsha, China.
Department of Pediatric Stomatology, Xiangya Stomatological Hospital, Central South University, Changsha, China.
BMC Cancer. 2021 Jul 20;21(1):836. doi: 10.1186/s12885-021-08547-4.
Immunotherapy is a crucial therapeutic approach in oncology. However, most patients with head and neck squamous cell carcinoma (HNSCC) do not derive benefit from immunotherapy. Vascular endothelial growth factor (VEGF)/VEGF Receptor 2 (VEGFR2) signaling pathway is one of the most important pathways regulating angiogenesis in tumor. The combination of immunotherapy and anti-angiogenic therapy is considered to improve efficacy of immunotherapy. The correlation between VEGF signaling pathway and tumor immune microenvironment in HNSCC patients is unclear.
We utilized RNA sequencing and clinical data of HNSCC patients from the TCGA database to study the correlation between VEGF signaling pathway and tumor immune microenvironment, on aspect of immune cell infiltration, immune-related gene expression profiling and immune-related biological pathways.
We observed that VEGF signaling pathway is positively correlated with immune cell infiltration, immune-related gene expression profiles, and the prognosis of HNSCC patients. The functional enrichment analysis of differentially expressed genes between different VEGF score subtypes detected multiple immune-related biological processes.
Our findings suggested that combining anti-VEGF signaling pathway agents with immunotherapy, such as immune checkpoint inhibitors (ICI) therapy, may exhibit encouraging benefits in HNSCC.
免疫疗法是肿瘤学中一种重要的治疗方法。然而,大多数头颈部鳞状细胞癌(HNSCC)患者并未从免疫疗法中获益。血管内皮生长因子(VEGF)/血管内皮生长因子受体 2(VEGFR2)信号通路是调节肿瘤血管生成的最重要通路之一。免疫疗法与抗血管生成疗法的联合应用被认为可以提高免疫疗法的疗效。VEGF 信号通路与 HNSCC 患者肿瘤免疫微环境之间的相关性尚不清楚。
我们利用 TCGA 数据库中 HNSCC 患者的 RNA 测序和临床数据,研究 VEGF 信号通路与肿瘤免疫微环境之间的相关性,包括免疫细胞浸润、免疫相关基因表达谱和免疫相关生物学途径。
我们观察到 VEGF 信号通路与免疫细胞浸润、免疫相关基因表达谱以及 HNSCC 患者的预后呈正相关。不同 VEGF 评分亚型之间差异表达基因的功能富集分析检测到多个免疫相关的生物学过程。
我们的研究结果表明,联合抗 VEGF 信号通路药物与免疫疗法,如免疫检查点抑制剂(ICI)治疗,可能对头颈部鳞状细胞癌患者带来令人鼓舞的益处。